Novartis Zometa label update
Executive Summary
Novartis updates labeling for its oncologic Zometa to include a precaution for osteonecrosis of the jaw. The precaution recommends that a dental examination with appropriate preventive dentistry be considered prior to beginning therapy in patients with concomitant risk factors (e.g. cancer, chemotherapy, corticosteroids, poor oral hygene). Novartis informed physicians of the Zometa (zoledronic acid) label change in a Sept. 24 "Dear Doctor" letter; the labeling changes were also made to Novartis' Zometa precursor Aredia...